Spelling suggestions: "subject:"ulcerative colitis"" "subject:"ulcerative politis""
31 |
Prebiotic activity of isomalto-oligosaccharidesKetabi, Ali Unknown Date
No description available.
|
32 |
The place of counselling in the care of people affected by inflammatory bowel diseaseThomas, Gillian B. January 1996 (has links)
No description available.
|
33 |
Effects of zinc on 2,4-dinitrobenzene sulfonic acid-induced ulcerative colitis in rats /Luk, Ho-hoi. January 2000 (has links)
Thesis (M. Med. Sc.)--University of Hong Kong, 2000. / Includes bibliographical references (leaves 73-90).
|
34 |
Effects of heparin on 2,4-dinitrobenzene sulfonic acid-induced ulcerative colitis and ethanol-induced gastritis in rats /Fung, Hon-sang. January 2000 (has links)
Thesis (M. Med. Sc.)--University of Hong Kong, 2000. / Includes bibliographical references (leaves 60-75).
|
35 |
Effects of heparin on 2,4-dinitrobenzene sulfonic acid-induced ulcerative colitis and ethanol-induced gastritis in ratsFung, Hon-sang. January 2000 (has links)
Thesis (M.Med.Sc.)--University of Hong Kong, 2000. / Includes bibliographical references (leaves 60-75). Also available in print.
|
36 |
Effects of zinc on 2,4-dinitrobenzene sulfonic acid-induced ulcerative colitis in ratsLuk, Ho-hoi. January 2000 (has links)
Thesis (M.Med.Sc.)--University of Hong Kong, 2000. / Includes bibliographical references (leaves 73-90). Also available in print.
|
37 |
Immunologyical mechanisms in primary primary sclerosing cholangitis : the role of the anti-neutrophil cytoplasmic antibodyBansi, Devinder Singh January 1997 (has links)
No description available.
|
38 |
The effect of a prebiotic with a probiotic on symptoms and quality of life in ulcerative colitisHaskey, Natasha 21 March 2007
The medical management of ulcerative colitis in children often requires aggressive pharmacological therapy or colonic resection. We hypothesized that synbiotic therapy, consisting of <i>B. longum</i> R0175 and inulin would improve symptoms and quality of life (QOL) in children diagnosed with ulcerative colitis. Consenting pediatric subjects (8-18 years; n = 9) with ulcerative colitis in remission were provided synbiotic therapy, (Probiotic: <i>Bifidobacterium longum</i> R0175 2.0 x 1010 cfu/day; Prebiotic: 15 g/day of inulin) (n = 4) or placebo (maltodextrin + ascorbic acid capsule; 15 g/day of non-resistant maltodextrin) (n = 5) for ten months in a pilot study (Phase I). After ten months, the study was unblinded and synbiotic therapy was administered to eight pediatric subjects (Phase II). In attempt to increase sample size, three adult subjects with active UC were recruited and provided the synbiotic therapy (Phase III). In all phases of the research, QOL was measured using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ was administered at baseline and every two months. Subjects kept a daily records of symptoms (stool consistency and frequency, presence of blood and mucous, presence of abdominal pain and overall feeling). Phase I QOL scores were significantly better for those receiving the synbiotic therapy versus the placebo (p = 0.014). Severe symptoms occurred in 60% of the control subjects, where as subjects receiving synbiotic therapy did not experience severe symptoms (p = 0.032). Phase II QOL scores were significantly better post-treatment with synbiotic therapy (p=0.034). One subject (steroid dependant) was able to wean off Prednisone® while receiving the synbiotic therapy; she remained in remission and was symptom free for over 26 months. In Phase III, synbiotic therapy did not induce remission in the adult subjects with active UC. No adverse effects were reported.<p>Synbiotic therapy consisting of <i>Bifidobacterium longum</i> R0175 and inulin, when provided in addition to conventional treatment, appears to be a safe and effective strategy for managing pediatric ulcerative colitis in remission.Further clinical trials are warranted to confirm these preliminary results.
|
39 |
The effect of a prebiotic with a probiotic on symptoms and quality of life in ulcerative colitisHaskey, Natasha 21 March 2007 (has links)
The medical management of ulcerative colitis in children often requires aggressive pharmacological therapy or colonic resection. We hypothesized that synbiotic therapy, consisting of <i>B. longum</i> R0175 and inulin would improve symptoms and quality of life (QOL) in children diagnosed with ulcerative colitis. Consenting pediatric subjects (8-18 years; n = 9) with ulcerative colitis in remission were provided synbiotic therapy, (Probiotic: <i>Bifidobacterium longum</i> R0175 2.0 x 1010 cfu/day; Prebiotic: 15 g/day of inulin) (n = 4) or placebo (maltodextrin + ascorbic acid capsule; 15 g/day of non-resistant maltodextrin) (n = 5) for ten months in a pilot study (Phase I). After ten months, the study was unblinded and synbiotic therapy was administered to eight pediatric subjects (Phase II). In attempt to increase sample size, three adult subjects with active UC were recruited and provided the synbiotic therapy (Phase III). In all phases of the research, QOL was measured using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ was administered at baseline and every two months. Subjects kept a daily records of symptoms (stool consistency and frequency, presence of blood and mucous, presence of abdominal pain and overall feeling). Phase I QOL scores were significantly better for those receiving the synbiotic therapy versus the placebo (p = 0.014). Severe symptoms occurred in 60% of the control subjects, where as subjects receiving synbiotic therapy did not experience severe symptoms (p = 0.032). Phase II QOL scores were significantly better post-treatment with synbiotic therapy (p=0.034). One subject (steroid dependant) was able to wean off Prednisone® while receiving the synbiotic therapy; she remained in remission and was symptom free for over 26 months. In Phase III, synbiotic therapy did not induce remission in the adult subjects with active UC. No adverse effects were reported.<p>Synbiotic therapy consisting of <i>Bifidobacterium longum</i> R0175 and inulin, when provided in addition to conventional treatment, appears to be a safe and effective strategy for managing pediatric ulcerative colitis in remission.Further clinical trials are warranted to confirm these preliminary results.
|
40 |
Study of the protective effects of polysaccharides from Angelica sinensis on ulcerative colitis in rats /Wong, Kai-chung. January 2006 (has links)
Thesis (M. Med. Sc.)--University of Hong Kong, 2006.
|
Page generated in 0.0596 seconds